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Carotid artery stenting has increased rates of
postprocedure stroke, death, and resource
utilization than does carotid endarterectomy in
the United States, 2005
James T. McPhee, MD,a Andres Schanzer, MD,b Louis M. Messina, MD,b and
Mohammad H. Eslami, MD,b Worcester, Mass
Objective: Carotid endarterectomy (CEA) remains the procedure of choice for treatment of patients with severe carotid
artery stenosis. The role of carotid artery stenting (CAS) in this patient group is still being defined. Prior single and
multicenter studies have demonstrated economic savings associated with CEA compared with CAS. The purpose of this
study was to compare surgical outcomes and resource utilization associated with these two procedures at the national level
in 2005, the first year in which a specific ICD-9 procedure code for CAS was available.
Methods: All patient discharges for carotid revascularization for the year 2005 were identified in the Nationwide Inpatient
Sample based on ICD9-CM procedure codes for CEA (38.12) and CAS (00.63). The primary outcome measures of
interest were in-hospital mortality and postoperative stroke; secondary outcome measures included total hospital charges
and length of stay (LOS). All statistical analyses were performed using SAS version 9.1 (Cary, NC), and data are weighted
according to the Nationwide Inpatient Sample (NIS) design to draw national estimates. Univariate analyses of categorical
variables were performed using Rao-Scott 2, and continuous variables were analyzed by survey weighted analysis of
variance (ANOVA). Multivariate logistic regression was performed to evaluate independent predictors of postoperative
stroke and mortality.
Results: During 2005, an estimated 135,701 patients underwent either CEA or CAS nationally. Overall, 91% of patients
underwent CEA. The mean age overall was 71 years. Postoperative stroke rates were increased for CAS compared with
CEA (1.8% vs 1.1%, P < .05), odds ratio (OR) 1.7; (95% confidence interval [CI] 1.2-2.3). Overall, mortality rates were
higher for CAS compared with CEA (1.1% vs 0.57%, P < .05) this difference was substantially increased in regard to
patients with symptomatic disease (4.6% vs 1.4%, P < .05). By logistic regression, CAS trended toward increased
mortality, OR 1.5; (95% CI .96-2.5). Overall, the median total hospital charges for patients that underwent CAS were
significantly greater than those that underwent CEA ($30,396 vs $17,658 P < .05).
Conclusions: Based on a large representative sample during the year 2005, CEA was performed with significantly lower
in-hospital mortality, postoperative stroke rates, and lower median total hospital charges than CAS in US hospitals. As
the role for CAS becomes defined for the management of patients with carotid artery stenosis, clinical as well as economic
outcomes must be continually evaluated. (J Vasc Surg 2008;48:1442-50.)Carotid artery stenting (CAS) has emerged as a techni-
cally feasible operation with obvious perceptible benefits,
most notably the potentially less invasive percutaneous
vascular access required to perform the procedure. Experi-
ence with other minimally invasive access techniques such
as iliac and aortic stent grafts has translated into equivalent
or improved operative morbidity1 and mortality2 with con-
comitant decrease in hospital length of stay and resource
utilization. The benefits of CAS, unlike other minimally
invasive vascular procedures, have not consistently trans-
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1442lated into demonstrably improved clinical outcomes com-
pared with carotid endarterectomy (CEA). In light of dis-
parate results of clinical3-6 as well as institutional7 and
population based trials,8 the indications for CAS remain
controversial.
For two procedures to achieve equipoise, in addition to
comparable risk-adjusted clinical outcomes, the overall cost
should not be significantly different in order to allow equal
access across all patient demographics. Kilaru et al, in a
decision analysis model, concluded that CAS could become
cost effective compared with CEA only if stroke and mor-
tality rates became equivalent.9 Similarly, previous studies
have demonstrated that CAS may be associated with in-
creased cost compared directly with CEA at the institu-
tional level.10-12
Prior to October 2004, no specific International Clas-
sification of Diseases Ninth Revision, Clinical Modification
(ICD9-CM) procedural code existed for CAS. Therefore,
previous works from administrative datasets relied on diag-
nostic codes and less specific procedural codes to evaluate
this procedure, leading to potential inaccuracies.2,8 There-
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CEA in terms of operative mortality and stroke rates limited
to 2005, themost recent available data, is lacking. Likewise,
a comparison of resource utilization between the two pro-
cedures at the national level is also lacking.
Our objective was to perform a national population-
based observational study exclusively in a 1-year period
(2005) during which a specific ICD9-CM code existed for
CAS. With results based on reliably coded data, the post-
operative stroke andmortality data as well as periprocedural
length of stay, hospital charges, and discharge disposition
of symptomatic and asymptomatic patients undergoing
CAS and CEA may be helpful to physicians in determining
the best treatment for their patients with carotid artery
occlusive disease.
METHODS
In order to evaluate surgical outcomes for patients under-
going carotid artery revascularization in theUnited States, we
used the Nationwide Inpatient Sample (NIS) for the calendar
year 2005, the most recent available data. The NIS is the
largest database of its kind and includes all-payer discharge
information from a national survey of 20% of all non-federal
hospitals in the United States. A complete overview and
description of the NIS is available on their website.13 The
studied cohort was comprised by linking the ICD9-CM pro-
cedure codes for all patient-discharges that occurred for either
CAS (00.63)14 or CEA (38.12) with the corresponding diag-
nostic code for carotid artery stenosis with (433.11) or with-
out (433.10) stroke.15 If a patient’s discharge diagnosis (di-
agnostic fields 1-15) was “carotid artery stenosis without
mention of stroke” with no accompanying secondary diag-
noses for transient ischemic attack (TIA), they were classified
as “asymptomatic”. If a patient’s discharge diagnosis was
either “carotid artery stenosis with stroke” or, if there was no
mention of stroke, but a secondary diagnosis code included
that for TIA, patients were classified as “symptomatic”
(Appendix, online only). A patientwas excluded from the final
dataset if they had procedural codes listed for both CAS and
CEA (1% of total) during the index admission in the interest
of keeping the cohorts as homogenous as possible to facilitate
comparison between the two procedure types. Hospital level
data were included in this analysis based on available informa-
tion provided by the American Hospital Association’s annual
survey of hospitals, a direct link to which is available through
the NIS dataset.13
The primary outcome measures for this retrospective
study were postoperative in-hospital stroke and death.
“Postoperative stroke” has a specific ICD9-CM code
(‘997.02’)15 therefore any patient undergoing CAS or
CEA that had this code under one of their secondary
ICD9-CM diagnostic codes (up to 15) was classified as
having had an iatrogenic stroke. Secondary outcome mea-
sures included resource utilization, namely hospital length
of stay, total hospital charges, and discharge disposition.
Detailed specific procedure cost information is unavailable
in the NIS therefore total hospital charges are used as a
surrogate for cost information. For those patients survivingto hospital discharge, their disposition is available. For the
purposes of analysis, this has been condensed to a dichot-
omous variable, home vs other (rehabilitation facility,
skilled nursing facility, nursing home, etc.).
Statistical analyses were performed using SAS version 9.1
(Cary, NC). A univariate analysis of categorical variables was
performed using Rao-Scott 2 and continuous variables were
analyzed by survey-weighted analysis of variance (ANOVA),
with a P  .05 considered statistically significant. The Elix-
hauser comorbidity software designed for use with adminis-
trative datasets was utilized to identify patient comorbidities
for the purposes of univariate andmultivariate analyses.16 This
software allows for accurate identification of pre-existingmed-
ical comorbidities, however, does not allow for comprehen-
sive risk stratification as the data of greatest clinical interest in
terms of risk stratification such as the degree of carotid steno-
sis, previous neck surgery, previous neck radiation, high ca-
rotid bifurcation, routine shunting/patch usage for CEA,
embolic protection device usage for CAS as well as informa-
tion on the degree of medical comorbidity such as echocar-
diogram and persantine thallium results as well as the degree
of neurologic disability from previous stroke, are not available
in this database.
Multivariate logistic regression was performed to deter-
Table I. Carotid revascularization patient characteristics,
2005
Factor Overall no. (%)
No. patients 135,701 (100)
Age (y)
Mean [SEM] 71 [0.11]
Median [range] 72 [23-98]
Age groups
60 17,450 (12.9)
60-69 38,558 (28.4)
70 79,693 (58.7)
Sex
Men 78,464 (57.9)
Women 57,147 (42.1)
Race
Non-white 9677 (9.7)
White 89,633 (90.3)
Presentation type
Asymptomatic 122,986 (92.1)
Symptomatic 10,495 (7.9)
Transient ischemic attack 5656 (4.2)
Stroke 4975 (3.7)
Procedure type
CEA 122,786 (90.5)
CAS 12,914 (9.5)
Hospital type
Non-teaching 77,625 (57.2)
Teaching 58,076 (42.8)
Hospital bed size
Small 8126 (6.0)
Medium 29,686 (21.9)
Large 97,888 (72.1)
Payer
Private/Medicare 128,596 (94.9)
Medicaid/self-pay 6947 (5.1)
CEA, Carotid endarterectomy; CAS, carotid artery stenting.mine which factors were independently predictive of post-
tive s
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tic regression were patient age, gender, insurance type,
comorbid conditions (hypertension, diabetes mellitus
[DM], chronic lung disease, coronary artery disease
[CAD], congestive heart failure [CHF], valvular heart dis-
ease, obesity, renal failure), symptom status (symptomatic
vs asymptomatic), procedure type performed (CAS vs
CEA) and hospital teaching status. Patient age was evalu-
ated as a categorical variable in the logistic regression.
The NIS provides a weighting strategy in order to draw
Fig 1. This series of bar graphs demonstrates the outc
larization, 2005. A, In-hospital mortality. B, Post-opera
Table II. Univariate analysis of patient characteristics base
disease, 2005
Factor
Overall
CEA CAS P
Overall number (%) 122,786 12,914 n/a
Mean age [SEM] 71 [.11] 70.9 [.28] .0001 7
Age groups .41
% 60 12.8 13.5
% 60-69 28.5 27.2
%  70 58.7 59.3
Gender
% Men 57.4 62.3 .0002
Comorbid conditions
% Hypertension 71.1 64.2 .0001
% Diabetes mellitus 26.3 25.3 .34
% Chronic lung disease 21.2 17.6 .004
% CAD/MI 10.8 11.0 .88
% CHF 6.8 11.4 .0001
% Valvular disease 6.5 7.5 .05
% Renal failure 3.0 3.9 .02
% Obesity 4.8 3.6 .02
Hospital type .0001
% Teaching 40.4 65.8
% Non-teaching 59.6 34.2
Hospital bed size .1
% Small 6.3 3.2
% Medium 22.4 16.8
% Large 71.3 80
Insurance type .27
% Private/Medicare 94.9 94.2
% Medicaid/self-pay 5.1 5.8
CAS, Carotid artery stenting; CEA, carotid endarterectomy.estimates at the national level based on a 20% annual surveyof hospitals. The statistical analyses are performed based on
these weighted numbers and therefore the data provided in
the results section are in the weighted format. This utiliza-
tion of survey weights to make observations regarding
surgical procedures at the national level is a method that has
been previously described.17,18
RESULTS
During the calendar year 2005, an estimated 135,701
patient discharges occurred for either CEA or CAS in the
for asymptomatic patients undergoing carotid revascu-
troke rate.
procedure type for asymptomatic and symptomatic
Asymptomatic Symptomatic
A CAS P CEA CAS P
684 11,302 n/a 9380 1116 n/a
.11] 71.6 [.23] .0001 69.5 [.28] 68.9 [.81] .0001
.19 .81
.3 11.5 18.1 19.5
.7 27.3 28.4 26.7
.0 61.2 53.5 53.8
.2 62.9 .0001 58.1 60.9 .42
.9 65.7 .0008 67.5 62.9 .11
.6 26.5 .94 24.1 21.3 .37
.8 17.9 .03 22.7 18.1 .13
11.8 .38 9.5 6.6 .17
.6 11.1 .0001 7.7 17.0 .0001
.4 7.7 .01 7.5 6.8 .69
.8 3.9 .002 3.3 2.6 .53
.8 3.6 .02 5.2 4.1 .49
.0001 .0001
.3 64.5 39.5 71.5
.7 35.5 60.5 28.5
.15 .002
.3 3.4 5.7 1.4
.3 17.1 25.1 12.3
.4 79.5 69.2 86.3
.66 .44
.2 95.0 92.1 90.1
.8 5.0 7.9 9.9omesd on
CE
111,
1.1 [
12
28
59
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11
6
6
2
4
40
59
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22
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95
4United States. The majority of patients were treated for
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age of patients underwent CEA (90.5%) than CAS (9.5%).
Table I contains overall demographic data for those under-
going CEA or CAS (Table I).
Overall patient characteristics by procedure. The
CEA patients had increased average age compared with the
CAS patients (71 vs 70.9, P .0001), although themedian
age was 72 for both groups. The distribution of age groups
was similar for both CEA and CAS patients (P .41).
Likewise the two groups were similar in terms of certain
comorbidmedical conditions such as diabetes mellitus (P
.34), coronary artery disease (P  .88), and valvular heart
disease (P .05). The two groups also had similar percent-
ages of patients with private insurance (P  .27) and were
treated at similarly sized hospitals (P  .1). The patients
undergoing CEA had a higher percentage of patients with
hypertension, chronic lung disease, and obesity (P  .05
for all), and weremore likely to be treated at a non-teaching
hospital (P .0001). In contrast, the CAS patients were
more likely to be male (P  .0002), and have a history of
CHF (P .0001), or renal failure (P  .02).
Univariate analysis of overall postoperative mor-
bidity and mortality. Patients that underwent CEA in
2005 had a significantly lower iatrogenic stroke rate (1.1%)
than did those that underwent CAS (1.8%), P  .0004.
Likewise patients that underwent CEA had a significantly
lower in-hospital mortality rate (.57%) than did the CAS
patients (1.1%), P  .004.
Univariate analysis of overall patient resource
utilization. The patients that underwent CEA had a
longer median hospital length of stay (2 days) than did
those that underwent CAS (1 day), P .0001. Overall, the
patients that underwent CEA were more likely to be dis-
charged to home after their procedure than the CAS pa-
tients (94.1% vs 91.9%, P  .008). The total median
hospital charges were greater for patients that were in-
cluded in the CAS group ($30,396) than those included in
the CEA group ($17,658), P .0001.
Univariate analysis of asymptomatic patient charac-
teristics. TheCEA andCAS patient groups for asymptom-
atic disease were similar in terms of the percentage of
patients greater than 70 years of age (P .19), hospital bed
size where they were treated (P  .15), as well as some
comorbid medical conditions, specifically diabetes mellitus,
coronary artery disease and obesity (all P values .05).
Compared with the CEA patients, the CAS patients had a
higher mean age (P  .0001), a higher percentage of male
patients (P  .0001), as well as a higher percentage of
patients with congestive heart failure (P  .0001), valvular
heart disease (P  .01), and renal failure (P  .002). In
contrast, the CEA patients had a higher prevalence of
hypertension (P .0008) and were much more likely to be
treated at a non-teaching hospital (59.7% vs 35.1%, P 
.0001) than the CAS patients (Table II).
Univariate analysis of asymptomatic patient post-
operative morbidity and mortality. Asymptomatic pa-
tients that underwent CEA for carotid artery stenosis had a
significantly lower postoperative stroke rate (.88%) than didthose that underwent CAS (1.6%), P  .001. The unad-
justed in-hospital mortality rate for CEA (.38%) was similar
to that of CAS (.57%), P  .18 (Fig 1, A and B).
Univariate analysis of asymptomatic patient re-
source utilization. Asymptomatic patients that under-
went CEA and CAS both had median hospital lengths of
stay of 1 day. The percentage of patients that were dis-
charged to a facility other than home was similar for CEA
(4.8%) and CAS (6.0%), P  .1. Patients that underwent
CEA had significantly lower median ($16,956) total hos-
pital charges compared with those patients that underwent
CAS ($28,853), P  .0001 (Table III).
Univariate analysis of symptomatic patient charac-
teristics. Symptomatic patients that underwent either CEA
or CAS for carotid artery stenosis were similar in terms of
patients that were older than 70 years (P  .81). Likewise,
the two groups were similar in the percentage of male
patients (P  .42), as well as the prevalence of certain
comorbid medical conditions, specifically hypertension, di-
abetes mellitus, chronic lung disease, coronary artery dis-
ease, renal failure, and obesity (all P values .05). Symp-
tomatic patients that underwent CEA had a higher mean
age (P  .0001) and were more likely to have their proce-
dure performed at a non-teaching hospital than the CAS
patients (P  .0001). In contrast, a higher percentage of
patients that underwent CAS had congestive heart failure
than did the CEA patients (P  .0001) and were more
likely to be treated at a large hospital (P .002) (Table II).
Univariate analysis of symptomatic patient postop-
erative morbidity and mortality. The symptomatic pa-
tients with carotid artery stenosis that underwent CEA had
a similar postoperative stroke rate (2.5%) to those that
underwent CAS (4.1%), P  .15. The unadjusted in-
hospital mortality rate was significantly lower for symptom-
atic patients that underwent CEA (1.4%) than those that
underwent CAS (4.6%), P  .0002. (Fig 2, A and B).
Univariate analysis of symptomatic patient resource
utilization. Symptomatic patients that underwent CEA
had a significantly shorter median (4 days) length of hospi-
tal stay compared with those that underwent CAS (5 days),
P  .0001. For CEA, a significantly greater percentage of
patients were discharged to home (84.9%) compared with
the CAS patients (73.9%), P .0001. In terms of total
hospital charges, those patients included in the CEA group
had significantly lower median ($29,894) total charges
compared with the CAS group ($49,535), P  .0001
(Table III).
Multivariate analysis of postoperative stroke. By
multivariate logistic regression, CAS was independently
predictive of postoperative stroke compared with CEA
(odds ratio [OR] 1.7; 95% confidence interval [CI] 1.2-
2.3, P  .003). Another factor that independently pre-
dicted postoperative stroke was presentation with symp-
tomatic disease (OR 2.8; 95% CI 2.1-3.8) (Table IV).
Multivariate analysis of in-hospital mortality. CAS
trended toward increased in-hospital mortality compared
with CEA but was not statistically significant (OR 1.5; 95%
CI .96-2.5, P  .08) after adjustment for multiple covari-
e stro
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conditions. Factors that were independently predictive of
increased in-hospital mortality included presentation with
symptomatic disease (OR 3.5; 95% CI 2.4-5.3, P.0001),
the presence of chronic lung disease (OR 2.0; 95% CI
1.3-3.0), congestive heart failure (OR 2.8; 95% CI 1.7-4.5,
P  .0001), and renal failure (OR 2.7; 95% CI 1.6-4.6)
(Table IV).
DISCUSSION
In this cross-sectional observational study of the most
recently available national data (2005), we have found that
overall, patients undergoing CAS had significantly higher
overall rates of postoperative stroke (1.8% vs 1.1%, P 
.0004), and in-hospital mortality (1.1% vs .57%, P .004)
than those undergoing CEA. By separate analysis, for pa-
tients with asymptomatic carotid artery stenosis, CAS was
associated with a nearly twofold higher postoperative stroke
rate than CEA (P  .001). For symptomatic patients with
carotid artery stenosis CAS was associated with a nearly
fourfold higher mortality rate than CEA (P  .0002). By
multivariate analysis after adjusting for presentation type,
age, gender, and multiple comorbid medical conditions,
patients that underwent CAS had higher odds of postoper-
ative stroke (1.7) than those that underwent CEA. Those
patients that underwent CAS trended toward but did not
achieve statistical significance in regard tomultivariate anal-
Fig 2. This series of bar graphs demonstrates the outco
ization, 2005. A, In-hospital mortality. B, Post-operativ
Table III. Postoperative outcomes and resource utilizatio
Factor CEA
In-hospital mortality (%) .57
Postoperative stroke (%) 1.1
Length of stay (d)
Median [range] 2 [0-117]
Total hospital charges ($)
Median [range] 17,658 [29-772,000
Discharge disposition
% Home 94.1
% Rehab, SNF, other 5.9
CAS, Carotid artery stenting; CEA, carotid endarterectomy.ysis of in-hospital mortality compared with those that un-derwent CEA. In terms of overall resource utilization, the
median total hospital charges were significantly greater for
those patients included in the CAS group (P .0001) and
a greater percentage of CAS patients treated for symptom-
atic disease were discharged someplace other than home
(P  .0006). For the symptomatic patient group, CAS
patients were more likely to be discharged to a facility other
than home (26.1% vs 15.1%, P  .0001).
As many providers anticipate the definitive results of
randomized controlled trials such as The Carotid Revascu-
larization Endarterectomy vs Stenting Trial (CREST),19
conflicting results have been published regarding the out-
comes of CEA compared with CAS. The clinical observa-
tions in the current work, that CAS is associated with
higher unadjusted in-hospital stroke and mortality rates,
are similar to those of previous population-based studies2,8
as well as large randomized multi-institutional trials.3,4
Nowygrod et al in their population-based work incorporat-
ing the years 1998 through 2003 found that for CAS,
procedural stroke (2.13%) and mortality (2.3%) rates were
greater than that for CEA with respective stroke and mor-
tality rates of 1.28% and .5% nationally.2 The current work
with similar respective overall stroke and mortality rates
nearly twofold higher for CAS compared with CEA focused
specifically on 2005 in which a dedicated ICD9 CM code
for CAS existed. Previous similar works, including our own,
or symptomatic patients undergoing carotid revascular-
ke rate.
presentation type CEA and CAS, 2005
Overall
CAS P
1.1 .004
1.8 .0004
.0001
1 [0-66]
.0001
30,396 [649-508,734]
.008
91.9
8.1mes fn by
]relied on a combination of specific diagnostic codes for
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procedural codes.2,8
Similar to our observations, collaborators for the End-
arterectomy versus Stenting in Patients with Symptomatic
Severe Carotid Stenosis3 in their large (N 527) random-
izedmulticenter trial determined that the 30-day risk of any
stroke or death of CAS was more than twofold greater than
that for CEA (relative risk 2.5) leading to early termination
of the trial. Likewise, a recent meta-analysis found CAS to
be associated with increased 30-day rates of stroke and
mortality compared with CEA.20 These results are in con-
trast to the immediate and long-term follow-up reports of
several industry-sponsored reports6,21-23 that have deter-
mined no significant difference is found in terms of stroke and
mortality rates between CAS and CEA, concluding that CAS
is a noninferior treatment modality to CEA.6,21-23 Because
the definition of what constitutes a “high-risk” surgical can-
didate as well as the proportion of symptomatic to asymp-
tomatic patients included in these trials is variable, it is
difficult to directly compare clinical outcomes. Of note, the
methodology of some of these industry sponsored regis-
tries, namely the heterogeneous case-mix, as well as the use
of a historical control as the surgical arm in a noninferiority
trial, has been previously critiqued.24,25
It is important to note that our group previously per-
formed a population-based clinical outcomes analysis of
CAS and CEA at the national level for the years 2003 and
2004, prior to the release of the dedicated ICD9-CM code
for CAS.8 The findings in our previous work demonstrated
significantly greater stroke and mortality rates overall, as
well as for asymptomatic and symptomatic groups sepa-
rately than reported here. The current work demonstrates
that in comparison, the gap between the outcomes for CEA
and CAS is possibly narrowing over time. The difference
between CEA andCAS for overall stroke (1.2%, P .0001)
and mortality (.91%, P  .0001) observed in the previous
study has narrowed such that in the current work the
difference in observed overall stroke (.7%, P  .001) and
mortality (.53%, P  .004) rates between CEA and CAS
was substantially less. More prominently, the stroke rate
gap between symptomatic patients undergoing CAS or
Table III. Continued.
Asymptomatic
CEA CAS P
.38 .57 .18
.88 1.6 .001
.0001
1 [0-110] 1 [0-53]
.0001
16,956 [29-632,341] 28,853 [649-508,734]
.1
95.2 94.0
4.8 6.0CEA substantially narrowed. In the 2003 and 2004 study,the difference in overall stroke rates was 3.1% in favor of
CEA, P  .0001. In the current work, the difference in
observed stroke rates between the two groups, although
still higher for CAS, was not statistically significant (1.6%,
P  .15). Likewise for mortality rates, the previous study
found an in-hospital survival advantage for symptomatic
patients of 6.5% (P  .0001) in favor of CEA. In the
current work, the observed difference was decreased to
3.2%. While the methodology of the two studies is some-
what different due to the change in ICD9-CM coding that
occurred in 2005, the design and endpoints of the two
studies are the same. Therefore, the finding that by 2005
the substantial observed differences between CEA and CAS
in 2003 and 2004 may be decreasing, is a noteworthy
finding. Most notably in the current work by multivariate
logistic regression, CAS was not an independent risk factor
for in-hospital mortality (P .08). This change over time,
to some degree, may reflect an improvement in patient
selection as more knowledge is gained regarding which
lesions are less likely to be amenable to CAS.26 Likewise,
over time there have likely been technical improvements in
overcoming the “learning curve” for CAS as has been
demonstrated in other complex surgical procedures.27
While not measurable in this type of study, the decreasing
stroke rates for CAS may also in part be attributable to the
universal application of embolic protection devices, which
are currently mandated by the Centers for Medicare and
Medicaid Services for reimbursement.
Due to the disparity in reported clinical results of CAS
compared with CEA, the forthcoming definitive results of
randomized controlled trials are eagerly anticipated. In the
interim, other measures of adequacy of performance be-
tween the two procedures have been evaluated such as
economic outcomes including length of stay data and cost
information. The current work found that for patients
undergoing either CEA or CAS, the difference in hospital
length of stay overall was largely negligible. The exception
to this observation was that for patients with symptomatic
disease, which showed that CAS patients had a lengthier
median (5 vs 4 days) hospital stay than the CEA patients. It
is not possible to determine if this increased length of stay
Symptomatic
CEA CAS P
1.4 4.6 .0002
2.5 4.1 .15
.0001
4 [1-67] 5 [0-66]
.0001
9,894 [482-568,181] 49,535 [4176-473,639]
.0001
84.9 73.9
15.1 26.12was related to the procedure itself or rather the other factors
carotid
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speech and swallow evaluations, physical therapy clearance
etc.). While no detailed specific procedure-related cost
information is available in this dataset, total hospital
charges, which have been previously used to compare out-
comes following complex surgical procedures,10,28 is avail-
able, and did demonstrate a marked difference between the
two procedures. Overall, the patients that were included in
the CAS group had significantly greater median total hos-
pital charges than those included in the CEA group. This
difference increased dramatically for the symptomatic pa-
tient cohort where CAS was associated with greatly in-
creased median total hospital charges compared with CEA.
It is important to recognize that this increase may likely be
due to factors unrelated to the procedure itself. To our
knowledge, this is the first study to evaluate total charges
for CEA and CAS at the national level. Previous economic
comparisons have been made between CEA and CAS, the
majority of which are confirmatory, demonstrating signifi-
cantly increased costs associated with CAS compared with
CEA.9-12 Park et al, in a single institution cost comparison
of CAS vs CEA, found that in a cohort of 94 patients with
equivalent clinical outcomes, CAS was associated with
higher total costs ($17,402 vs $12,112, P  .029) than
CEA.10 They attributed the majority of the cost difference
to direct procedure-related materials as noted by the differ-
ence between surgical vs angiography suite supplies for
CAS ($15,407) compared with CEA ($1953), P .001.10
Table IV. Multivariate analyses of in-hospital mortality an
Factor
In-hosp
OR 95
Sex
Men (vs women) 1.3 .8
Age group
70 (vs 60) 1.5 .7
70 (vs 60-69) 1.3 .8
Insurance type
Private (vs Medicaid/self-pay) 1.1 .4
Comorbid conditions
Hypertension (vs none) .53 .3
Diabetes (vs none) 1.2 .8
Chronic lung disease (vs none) 2.0 1.
Coronary artery disease/MI (vs none) .28 .1
Congestive heart failure (vs none) 2.8 1.
Valvular heart disease (vs none) .88 .4
Obesity (vs none) .51 .1
Renal failure (vs none) 2.7 1.
Presentation type
Symptomatic (vs asymptomatic) 3.5 2.
Procedure type
CAS (vs CEA) 1.5 .9
Hospital teaching status
Non-teaching (vs teaching) 1.1 .7
Hospital bed size
Large (vs small) 1.8 .7
Medium (vs small) 1.6 .6
OR, Odds ratio; CI, confidence intervals; MI, myocardial infarction; CAS,Similarly Kilaru et al, in a comprehensive Markov decisionanalysis model, concluded that CAS costs more and is less
effective than CEA.9 While it is not possible to directly
compare cost results from single institutional and decision
analysis models with the total hospital charges reported in a
large national database, the trends observed in three studies
with three distinct methodologies are very similar. It is
important to note that the total charges in this study are not
direct procedure-related costs but rather the total charges
associated with the index hospital stay. In contrast to the
above studies as well as our findings, one study was encoun-
tered that found CEA to be a costlier procedure than CAS.
Gray et al, in their single institutional review of 272 carotid
artery procedures, found that CEA was associated with
higher cost than CAS. Of note, their group found no
difference in direct procedure costs for CAS and CEA (P
.1), and report 0% stroke and mortality rates in the CAS
arm, findings that make their results difficult to generalize
to other populations.29
While causality cannot be proven in administrative
datasets, we offer that one possible explanation for the large
discrepancy in hospital charges between CAS and CEA
beyond the cost differential associated with the procedure
itself, may be the increased postoperative mortality and
stroke rate overall as well as the increased length of stay
required by the symptomatic patients that underwent CAS.
This is intuitive as those patients that suffered a postoper-
ative stroke or ultimately died or were unable to be dis-
charged to home likely had a more complicated hospital
st-procedure stroke for carotid revascularization, 2005
ortality Post-procedure stroke
P OR 95% CI P
.22 .24
.86 .68-1.1
.36 .94
1.1 .74-1.6
1.0 .76-1.4
.8 .31
.78 .48-1.3
.0003 .82 .64-1.0 .11
.38 .92 .7-1.2 .57
.001 1.1 .78-1.4 .75
.007 1.1 .74-1.6 .7
.0001 1.4 .90-2.0 .14
.70 .98 .64-1.5 .94
.17 .93 .54-1.6 .78
.0004 .93 .44-1.9 .84
.0001 .0001
2.8 2.1-3.8
.08 .003
1.7 1.2-2.3
.79 .35
.88 .66-1.2
.45 .06
.74 .47-1.2
1.1 .63-1.8
artery stenting; CEA, carotid endarterectomy.d po
ital m
% CI
7-1.9
4-2.9
4-2.1
4-2.9
7-.75
1-1.7
3-3.0
1-.71
7-4.5
4-1.7
9-1.3
6-4.6
4-5.3
6-2.5
2-1.6
0-4.8
0-4.5course with more intensive multidisciplinary care, diagnos-
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Volume 48, Number 6 McPhee et al 1449tic work-ups and secondary interventions all of which
would be included in the nonspecific total hospital charge
category.
The limitations of studies based on administrative data-
sets such as the NIS have been described previously.30 The
main limitations specific to this study pertain to unknown
clinical factors that may represent an inherent selection bias
in favor of CEA. We have no knowledge of anatomical
factors namely degree of carotid artery stenosis, previous
neck surgery or radiation or whether a patient was deemed
medically too high risk for CEA and therefore underwent
CAS. We have attempted to account for certain patient
comorbid medical conditions using validated software,
however, this is limited information and does not speak to
the severity of a patients’ disease state, which would repre-
sent a selection bias whereby the sickest and highest risk
patients likely underwent CAS. Similarly, total hospital
charges as a marker of economic impact of a surgical
procedure provides only crude information and, therefore,
in this study is used as a surrogate for cost information and
conclusions should be drawn with this fact in mind. It is
unable to be shown which portion of the charges is attrib-
utable to the procedure itself. Patient factors unrelated to
the procedure including diagnostic evaluations for comor-
bid conditions, consultations, and imaging costs are all
included in this charge information and these unmeasured
factors may account for the majority of the hospital charge
discrepancy. This may again represent a selection bias in
that the CAS patients were likely high risk for open surgery
and therefore would likely incur greater hospital cost re-
lated to their comorbidity which would contribute to the
discrepancy observed in terms of total hospital charges.
Previous works have utilized this total hospital charge
information,11,28 and the fact that the observations in the
current study are congruent with the findings of other
published data on the subject tempers this limitation to
some degree. In this study, the percentage of asymptomatic
patients is higher than expected (92%). Patients that were
miscoded under diagnostic codes other than carotid steno-
sis may have been inappropriately classified as asymptom-
atic. To minimize this effect all secondary diagnoses (up to
15) of TIA or stroke were included as a means of further
identifying the symptomatic group. However, because
these data are collected at the time of patient discharge the
code for carotid stenosis with or without the presence of
symptoms was used to initially stratify the patient groups by
symptoms. Coding inaccuracies in terms of patient case-
mix, such as prevalence of comorbidities, or complications
such as postoperative stroke are possible. To minimize
these inaccuracies, we used established comorbidity soft-
ware to attempt to appropriately characterize patients with
pre-existing comorbid conditions.16 Likewise, to identify
iatrogenic stroke, we used an established ICD9-CM code.
If patients were miscoded under other less-specific stroke
codes, they may have been missed in this postoperative
stroke analysis, however, there is no reason to suspect that
this miscoding would bias one procedure type over an-
other. Additionally, in-hospital outcomes are a suboptimalmeasure of overall success when evaluating surgical inter-
ventions. Ideally long-term information such as 30-day and
1-year stroke and mortality rates would be used because we
are evaluating procedures whose goal is to limit long-term
stroke risk. Likewise, we may be underestimating postop-
erative stroke and mortality rates due to the lack of 30-day
data. Unfortunately, due to the arduous patient de-identi-
fication process employed by the NIS, follow-up informa-
tion is unavailable. It is important to recognize that the
observations made in this work regarding mortality, post-
operative stroke and resource utilization related to CEA
and CAS are likely multifactorial. We are unable to deter-
mine to what extent a patient’s mortality, morbidity, LOS
or hospital charge is directly attributable to the procedure
itself or whether it was related to a pre-existing comorbidity
or other mitigating factor. To attempt to temper this
limitation we included as many cofactors as possible in the
multivariate analysis.
CAS has gained wide popularity, and annual volume
seems to be increasing nationwide.31 Despite this technical
feasibility and wide procedural application, controversy
continues to surround patient selection for this procedure,
specifically in terms of application in the asymptomatic
population. This was denoted by the Center for Medicare
and Medicaid services when they reversed their initial pro-
posal to widely expand coverage for carotid artery stenting
in May, 2007. Of interest, it seems that over time, the
outcomes for CASmay be improving, and the current work
shows that by 2005 the previously large gap between CEA
and CAS may be narrowing. However, if stenting is to gain
universal application, its clinical outcomes in terms of
stroke and mortality rates should be equivalent to CEA and
the associated costs must not be prohibitive to allow appli-
cation to all patient groups, which the current and previous
data do not yet support.
CONCLUSION
During the year 2005, the most recently available na-
tional data, within the limitations of a large administrative
dataset, which include a lack of comprehensive risk stratifi-
cation by procedure type, we have found that patients that
underwent CAS had an overall increased postoperative
stroke and mortality rate compared with those that under-
went CEA. Further, those patients that underwent CAS
had an increase in crude total hospital charges associated
with their hospitalization compared with those that under-
went CEA. These observations indicate that the anticipated
forthcoming results of randomized controlled trials will be
of critical importance in determining the future applicabil-
ity of CAS in patients with carotid artery stenosis.
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Diagnosis Diagnostic code
Carotid artery occlusion and stenosis
without mention of cerebral
infarction
433.10
Carotid artery occlusion and stenosis
with cerebral infarction
433.11
Multiple and bilateral carotid artery
occlusion and stenosis without
mention of cerebral infarction
433.30
Multiple and bilateral carotid artery
occlusion and stenosis with
cerebral infarction
433.31
Transient cerebral ischemia 435.9
Amaurosis fugax 362.34
Iatrogenic cerebrovascular infarction
or hemorrhage; Postoperative
stroke
997.02dural codes
Procedure Procedural code
Carotid endarterectomy 38.12
Percutaneous insertion of carotid
artery stent
00.63
